Cerenome (CNSY) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
14 May, 2026Opening remarks and agenda
Meeting called to order at 9:01 A.M. Eastern Time on May 14, 2026, chaired by the President and CEO.
Agenda included consideration of proposals set forth in the proxy statement dated March 31, 2026.
No Q&A session was held; stakeholders were directed to investor relations for questions.
Board and executive committee updates
Proposal to elect six members to the board for one-year terms was presented and approved.
Shareholder proposals
Four proposals were considered: board election, ratification of auditors, advisory vote on executive compensation, and amendment of the 2020 Stock Incentive Plan.
The adjournment proposal was not brought to the floor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cerenome
- Q2 2026 marked rebranding, clinical progress, and a $9.0M net loss amid capital constraints.CNSY
Q2 2026 - Cerenome rebrands and advances CNS oncology with integrated therapeutics, diagnostics, and AI.CNSY
Investor update - Shelf registration allows flexible securities offerings; Canaccord Genuity LLC is distribution agent.CNSY
Registration filing - At-the-market equity offering of up to $17.35M targets CNS cancer innovation, with dilution risk.CNSY
Registration filing - 186RNL shows safety, efficacy, and immune activation in leptomeningeal metastases.CNSY
2026 AANS Annual Scientific Meeting presentation - Net loss narrowed, cash and investments rose, and funding remains critical amid clinical and commercial progress.CNSY
Q1 2026 - Key votes include director elections, auditor ratification, and executive pay approval.CNSY
Proxy filing - $15M raise funds pivotal trials, CNSide scale-up, and 2026 commercial expansion.CNSY
Business update - $15M financing and clinical progress support CNSide's 2025 launch and CNS cancer milestones.CNSY
Q4 2024